Atricure, Inc. Appoints Shlomi Nachman as Director, Member of Each of the Board?s Strategy Committee and Compliance, Quality and Risk Committee
February 27, 2024 at 08:50 am EST
Share
On January 4, 2024 AtriCure, Inc. filed a Current Report on Form 8-K reporting that the Company?s Board of Directors elected Shlomi Nachman to serve as a director until the Company?s next Annual Meeting of Stockholders. This Current Report on Form 8-K amends the Original Form 8-K for the purpose of reporting that effective February 22, 2024, the Board elected Mr. Nachman to serve as a member of each of the Board?s Strategy Committee and Compliance, Quality and Risk Committee.
AtriCure, Inc. provides technologies for the treatment for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management. The Company's cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Its pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures. The Company's products for open and minimally invasive ablation include Isolator Synergy Clamps and Multifunctional Pens and Linear Ablation Devices. Its products for open ablation include cryoICE Cryoablation System. Its products for minimally invasive ablation include EPi-Sense Guided Coagulation System with VisiTrax Technology. Its appendage management products include AtriClip System. The Isolator Synergy Ablation System clamps are single-use disposable radio frequency (RF) products with jaws that close in a parallel fashion.